Yasin Keshvargar
Lawyers
Filters
Metagenomi $93.75 million IPO
The shares are listed on the Nasdaq Global Market
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064
Immunocore Holdings $402.5 million convertible notes offering
The 2.5% convertible notes are due 2030
Immatics $201 million follow-on offering
We advised Immatics on the offering of shares
Solid Biosciences $109 million private placement
The PIPE includes common stock and pre-funded warrants
XPO $585 million notes offering
The 7.125% senior unsecured notes are due 2032
Merit Medical Systems $747.5 million convertible senior notes offering
The 3% convertible senior notes are due 2029
Evolent Health $402.5 million convertible notes offering
The convertible notes are due 2029
Samarco Mineração restructuring
We advised an ad hoc group of financial creditors in one of the first creditor-proposed Brazilian restructurings
Polaris $500 million debut senior notes offering
We advised Polaris on its inaugural investment-grade notes offering